Additionally, various pre-clinical trials have demonstrated the synergistic beneficial outcome of targeting PD-1/PD-L1 axis and other inhibitory immune checkpoint molecules including TIM-3, LAG-3, VISTA, BTLA and TIGIT in terms of tumor growth control and overall survival (103–108). Here, HAVCR2 is linked to neoplasm.